Newgenivf Group Ltd income statement

In fiscal 2025, Newgenivf Group Ltd reported revenue of $23.7m, up 336.3% on the year before, operating income of −$10.7m (a -45.2% margin) and net income of $9.9m, or $3.04 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Newgenivf Group Ltd: income statement, annual
Fiscal year	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	4	6	5	5	24
Cost of revenue	3	4	3	4	4
Gross profit	1	2	2	2	1
Selling and marketing	0	0	0	0	1
General and administrative	1	1	2	3	10
Operating income	0	0	0	−1	−11
Interest expense	—	—	0	1	1
Provision for credit losses	—	—	—	0	—
Income before tax	0	0	0	−1	10
Income tax	0	0	—	−0	—
Net income	−0	0	0	−1	10
Diluted EPS	$0.00	$4.72	$13019.30	−$4408.76	$3.04
Diluted shares (average)	—	—	—	—	3m
EBITDA	0	0	0	−1	−11

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: BMGL vs NIVF CCM vs NIVF NIVF vs SNDA

More: Health Care Facilities stocks compared, Health Care sector, rankings of US companies

Figures from Newgenivf Group Ltd's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Newgenivf Group Ltd.